Astellas muscle deal pumps new funding into Cytokinetics
This article was originally published in Scrip
Executive Summary
The US firm Cytokinetics will receive at least $40 million in upfront and reimbursement payments for R&D activities over the first two years of a new collaboration with Astellas for skeletal muscle activators (SMAs).